title: Endocannabinoids blunt the augmentation of synaptic transmission by serotonin 2A receptors in the nucleus tractus solitarii (nTS).
abstract: Serotonin (5-Hydroxytryptamine, 5-HT) and the 5-HT2 receptor modulate cardiovascular and autonomic function in part through actions in the nTS, the primary termination and integration point for cardiorespiratory afferents in the brainstem. In other brain regions, 5-HT2 receptors (5-HT2R) modify synaptic transmission directly, as well as through 5-HT2AR-induced endocannabinoid release. This study examined the role of 5-HT2AR as well as their interaction with endocannabinoids on neurotransmission in the nucleus tractus solitarii (nTS). Excitatory postsynaptic currents (EPSCs) in monosynaptic nTS neurons were recorded in the horizontal brainstem slice during activation and blockade of 5-HT2ARs. 5-HT2AR activation augmented solitary tract (TS) evoked EPSC amplitude whereas 5-HT2AR blockade depressed TS-EPSC amplitude at low and high TS stimulation rates. The 5-HT2AR-induced increase in neurotransmission was reduced by endocannabinoid receptor block and increased endogenous endocannabinoids in the synaptic cleft during high frequency, but not low, TS stimulation. Endocannabinoids did not tonically modify EPSCs. These data suggest 5-HT acting through the 5-HT2AR is an excitatory neuromodulator in the nTS and its effects are modulated by the endocannabinoid system.
authors.affiliation: Department of Biomedical Sciences & Dalton Cardiovascular Research Center, University of Missouri, 134 Research Park Drive, Columbia, MO 65211, USA.
authors.forename: James R
authors.initials: JR
authors.lastname: Austgen
authors.forename: David D
authors.initials: DD
authors.lastname: Kline
mesh_terms: D000818:Animals; D063388:Endocannabinoids / Q000494:pharmacology*; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects* / Q000502:physiology; D012701:Serotonin / Q000378:metabolism; D017552:Solitary Nucleus / Q000187:drug effects* / Q000502:physiology; D013569:Synapses / Q000187:drug effects*; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology
chemical_list: D063388:Endocannabinoids; D044402:Receptor, Serotonin, 5-HT2A; D012701:Serotonin
keywords: Autonomic nervous system; Neuromodulator crosstalk; Serotonin receptors
references.citation: J Neurophysiol. 2009 Jan;101(1):5-7
references.pmid: 19004992
references.citation: J Comp Neurol. 2003 Jan 6;455(2):270-80
references.pmid: 12454991
references.citation: Physiol Rev. 2009 Jan;89(1):309-80
references.pmid: 19126760
references.citation: J Auton Nerv Syst. 1995 Dec 5;56(1-2):119-24
references.pmid: 8786274
references.citation: Neuropharmacology. 2009;56 Suppl 1:213-25
references.pmid: 18762202
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1994 May;349(5):447-54
references.pmid: 8065458
references.citation: J Med Chem. 2006 Sep 21;49(19):5794-803
references.pmid: 16970404
references.citation: Neuroreport. 2002 Dec 3;13(17):2365-9
references.pmid: 12488828
references.citation: J Neurochem. 2006 Nov;99(4):1164-75
references.pmid: 17010161
references.citation: Neuroscience. 2010 May 5;167(2):510-27
references.pmid: 20153814
references.citation: J Comp Neurol. 1999 Jun 28;409(2):187-209
references.pmid: 10379914
references.citation: Exp Physiol. 2005 Mar;90(2):175-81
references.pmid: 15604109
references.citation: Neurosci Lett. 2005 Jun 24;381(3):334-9
references.pmid: 15896495
references.citation: J Neurochem. 2007 Dec;103(5):2111-20
references.pmid: 17944876
references.citation: J Med Chem. 1992 Dec 25;35(26):4903-10
references.pmid: 1479590
references.citation: J Pharmacol Exp Ther. 2009 Oct;331(1):186-96
references.pmid: 19592666
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):437-47
references.pmid: 17021259
references.citation: Neuropsychopharmacology. 2009 Jul;34(8):1979-92
references.pmid: 19212317
references.citation: Eur J Pharmacol. 2005 May 23;516(1):28-33
references.pmid: 15913602
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9870-5
references.pmid: 17535909
references.citation: Brain Res. 2005 Oct 19;1059(2):197-202
references.pmid: 16154548
references.citation: Br J Pharmacol. 1999 Nov;128(6):1307-15
references.pmid: 10578146
references.citation: Neuropharmacology. 2011 Sep;61(3):414-20
references.pmid: 21354188
references.citation: Eur J Pharmacol. 1998 Oct 16;359(1):49-54
references.pmid: 9831292
references.citation: J Neurosci. 2010 Apr 14;30(15):5303-10
references.pmid: 20392952
references.citation: Br J Pharmacol. 2000 Dec;131(7):1445-53
references.pmid: 11090119
references.citation: Neuroscience. 2002;113(1):23-35
references.pmid: 12123681
references.citation: Auton Neurosci. 2010 Dec 8;158(1-2):44-50
references.pmid: 20580326
references.citation: J Neurophysiol. 2011 Oct;106(4):1822-32
references.pmid: 21734104
references.citation: Neuron. 2010 Mar 11;65(5):657-69
references.pmid: 20223201
references.citation: Neuroscience. 2007 May 11;146(2):792-801
references.pmid: 17367942
references.citation: J Neurophysiol. 1986 May;55(5):1076-90
references.pmid: 3012009
references.citation: J Physiol. 2003 Jul 1;550(Pt 1):149-58
references.pmid: 12879865
references.citation: J Neurophysiol. 2012 Oct;108(8):2292-305
references.pmid: 22855775
references.citation: Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
references.pmid: 11888546
references.citation: J Neurosci. 2001 Feb 15;21(4):1104-9
references.pmid: 11160380
references.citation: Neuroscience. 2011 Oct 13;193:54-62
references.pmid: 21820490
references.citation: J Neurosci. 2012 Nov 14;32(46):16530-8
references.pmid: 23152635
references.citation: Brain Res. 2008 Mar 20;1200:1-9
references.pmid: 18308297
references.citation: J Neurochem. 2009 May;109(3):935-44
references.pmid: 19302195
references.citation: J Neurosci. 2012 Apr 11;32(15):5237-41
references.pmid: 22496569
references.citation: Synapse. 2002 May;44(2):64-75
references.pmid: 11891878
references.citation: Pharmacol Ther. 1998 Sep;79(3):231-57
references.pmid: 9776378
references.citation: Curr Neuropharmacol. 2006 Apr;4(2):101-14
references.pmid: 18615128
references.citation: Auton Neurosci. 2009 Oct 5;150(1-2):82-93
references.pmid: 19464961
references.citation: J Physiol. 2004 Sep 15;559(Pt 3):923-38
references.pmid: 15272041
references.citation: Diabetes. 2010 Aug;59(8):1890-8
references.pmid: 20522593
references.citation: Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):348-53
references.pmid: 23248270
references.citation: Psychopharmacology (Berl). 2010 Sep;212(1):13-23
references.pmid: 19823806
references.citation: Neuroscience. 2011 Dec 1;197:107-20
references.pmid: 21963868
references.citation: Eur J Neurosci. 2007 Jul;26(2):345-54
references.pmid: 17623018
references.citation: J Pharmacol Exp Ther. 2001 Dec;299(3):1106-11
references.pmid: 11714900
references.citation: J Neurosci. 2008 Jun 18;28(25):6508-15
references.pmid: 18562622
references.citation: J Neurosci. 2002 Sep 1;22(17):7509-17
references.pmid: 12196574
references.citation: Pharmacol Ther. 2009 Feb;121(2):160-73
references.pmid: 19109993
references.citation: Prostaglandins Other Lipid Mediat. 2005 Sep;77(1-4):111-22
references.pmid: 16099396
references.citation: J Neurosci. 2004 May 19;24(20):4865-74
references.pmid: 15152047
references.citation: Cell Mol Neurobiol. 2003 Oct;23(4-5):709-26
references.pmid: 14514026
references.citation: Nat Neurosci. 2010 May;13(5):592-600
references.pmid: 20348918